Acumen Wealth Advisors LLC Reduces Stock Holdings in Haleon PLC Sponsored ADR $HLN

Acumen Wealth Advisors LLC lowered its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 25.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 291,363 shares of the company’s stock after selling 99,258 shares during the quarter. Acumen Wealth Advisors LLC’s holdings in Haleon were worth $2,917,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC acquired a new stake in shares of Haleon during the fourth quarter worth about $187,000. AQR Capital Management LLC grew its position in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after acquiring an additional 17,720 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Haleon by 7.6% in the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after acquiring an additional 5,178 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Finally, CW Advisors LLC raised its position in Haleon by 11.6% in the 2nd quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HLN. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Haleon Price Performance

Shares of NYSE HLN opened at $9.94 on Wednesday. The stock has a fifty day moving average price of $9.31 and a 200 day moving average price of $9.86. Haleon PLC Sponsored ADR has a 1-year low of $8.65 and a 1-year high of $11.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The company has a market cap of $43.76 billion, a PE ratio of 25.47, a P/E/G ratio of 2.32 and a beta of 0.13.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.